The radioisotope-labeled anti-CD55 antibody conjugated with 177Lu demonstrated its potential as a therapeutic agent by significantly reducing tumor growth and increasing the median survival time in a pleural metastatic lung cancer mouse model37. This evidence concerns the gene CD55 and neoplasm.